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Background: Glycogen Phosphorylase BB (GPBB) is considered an early and speciﬁ  c marker of myocardial necrosis 
and ischemia. A POCT kit GPBB for diagnostic use has recently been approved. 
Aim: an evaluation of the correspondence of qualitative POCT GBPP measurements with ELISA test results. 
Material and methodology: 20 individuals with non-ST elevation myocardial infarction (non-STEMI) and 20 probands 
without acute coronary syndrome (ACS) were tested. GPBB (POCT, ELISA) in venous plasma (lithium-heparin) was 
assayed in all probands. 
Results: individuals with non-STEMI had signiﬁ  cantly higher GPBB ELISA values (32.3 vs. 6.1 μg/l; p < 0.01). 
GPBB sensitivity and speciﬁ  city for non-STEMI presence 6 hours after chest pain generation were 100 %. No proband 
was classiﬁ  ed in a diﬀ  erent subgroup with POCT of GPBB (positive/negative). GPBB POCT correlate with a non-
STEMI diagnosis (χ2 36.1; p < 0.01).
Conclusion: GPBB POCT measurement is comparable with ELISA test results. GPBB analysis could expand the 
diagnostic palette in the ﬁ  rst hours after the onset of acute coronary syndrome. 
INTRODUCTION
Routinely used laboratory markers for the presence 
of myocardial necrosis are similar in that they diag-
nose myocardial necrosis relatively late (for example, 
cardiac troponins) or they are characterized by low 
speciﬁ  city (for example, myoglobin or albumin binding 
cobalt-ACB)(ref.1, 8, 9). Even more problematic is the situ-
ation in diagnosing the presence of myocardial ischemia 
without necrosis when regularly-used markers are non-spe-
ciﬁ  c and the diagnostician can be burdened by a relatively 
large error rate (for example, ACB)1. 
From this perspective Glycogen Phosphorylase 
Isoenzyme BB (GPBB) appears to be a promising, early 
speciﬁ  c marker of myocardial necrosis (early release after 
the ﬁ  rst two hours). In addition, information has recently 
appeared regarding its diagnostic use in the assessment of 
reversible myocardial ischemia1–3. A few years ago the ﬁ  rst 
diagnostic kits for measuring GPBB (ELISA, Diagenics) 
appeared on the market7; in our own group of individuals 
suspected of having acute coronary syndrome we veri-
ﬁ  ed the great diagnostic eﬃ   ciency of this marker in the 
early stages of myocardial necrosis and ischemia11. As the 
manufacturer of the ELISA kit also oﬀ  ers the possibility 
of determining GPBB through POCT (point-of-care-test), 
we posited the question in our work whether GPBB re-
sults obtained by the POCT method are comparable with 
the results obtained from the ELISA test.
METHOD
Forty individuals hospitalized in the Department of 
Internal Medicine at Šternberk Hospital for suspected 
acute coronary syndrome (ACS) were chosen for testing. 
Twenty of these patients were diagnosed as positive (acute 
myocardial infarction without ST segment elevation) and 
twenty were diagnosed as negative. 
The ﬁ  nal diagnosis of non-STEMI (non-ST elevation 
myocardial infarction) / non-coronary diﬃ   culties was 
made on the basis of ESC/AAC criteria (medical histo-
ry, clinical ﬁ  ndings, EKG, troponins, echocardiography); 
only individuals with a positive coronarographic ﬁ  nding 
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the group of patients with ACS evaluated in our study. 
The patients that we put in the non-coronary pain cat-
egory had negative troponin, negative echocardiographic 
and electrocardiographic ﬁ  ndings; the source of pain was 
subsequently determined for these patients (by exercise 
test with bicycle ergometry, and if necessary SPECT, 
neurological examination, pneumological examination, 
rehabilitation examination, and similar methods) and 
was explained as non-coronary (for example thoracalgia 
musculoskeletal etiology, vegetative dystonia, pleural syn-
drome, and others). 
Venous blood was drawn from all individuals in the 
framework of this study for the purpose of determining 
GPBB. In all patients, the laboratory examination of 
GPBB in venous blood was made immediately after ad-
mission (6 hours of chest pain in patient’s history at the 
most; mean period of chest pain since the beginning was 
3.2 hours). The blood was placed in tubes with lithium-
heparin (Sarstedt, catalogue no. 04.1936); within thirty 
minutes from the time the blood was drawn separation 
was performed on the samples in a cooled centrifuge 
(3,000 g, 10 min.) to acquire plasma frozen to –80 0C. 
ELISA and POCT tests were conducted simultaneously 
within 90 days of the freezing. ELISA kit developer de-
clared stability of GPBB in noted temperature for the 
duration of storage.
The data were processed using the Medcalc pro-
gramme (Belgium). The Komolgorov-Smirnov test was 
used to evaluate the normality of the GPBB data from 
the ELISA test. Continuous values were expressed as the 
means ± standard deviations and median. ANOVA was 
used to evaluate GPBB-ELISA for the presence of ACS 
and ROC analysis was used to evaluate diagnostic eﬃ   -
ciency. A value p < 0.05 was considered to be statistically 
signiﬁ  cant.
RESULTS 
Twenty individuals were determined to be non-STEMI, 
while the remaining twenty diﬃ   culties were determined 
to be non-coronary.
Non-STEMI patients had signiﬁ  cantly higher GPBB-
ELISA values (Tab. 1). The sensitivity and speciﬁ  city of 
GPBB for the presence of non-STEMI 6 hours after chest 
pain generation amounted to 100 % with cut-oﬀ   value of 
8.5 μg/l (Fig. 1). When the manufacturer’s recommended 
cut-oﬀ   value was used (10 μg/l) the sensitivity and speciﬁ  -
city results remained the same.
A comparison of the ELISA results using the manu-
facturer’s recommended cut-oﬀ   value showed that all 40 
examined individuals (100 %) were correctly identiﬁ  ed as 
positive (20 patients) and negative (20 patients). None 
of the patients was diagnosed diﬀ  erently (positive/nega-
tive) the POCT method and during the interpretation of 
ELISA results. A table with four ﬁ  elds shows that the 
GPBB POCT results correspond with the non-STEMI 
diagnosis (36.1; p < 0.01).
DISCUSSION 
Glycogen Phosphorylase (Glycogen Phosphorylase; 
-1.4-D-glucan: orthophosphate D-glucosyltrans  ferase; 
GPBB; EC 2.4.1.1) is a glycolytic enzyme that plays an 
essential role in the regulation of carbohydrate metabo-
lism. It catalyzes the ﬁ  rst step of glycogenolysis, in which 
glycogen is converted to glucose 1-phosphate (mobilizes 
glycogen, which is connected to the delivery of glucose). 
These conditions appear during ischemia and hypoglycae-
mia. GPBB is connected with glycogen in a macromolecu-
lar complex that is structurally bound to the sarcoplasmic 
reticulum (the sarcoplasmic reticulum glycogenolysis com-
plex). The degree of GPBB association with this complex 
depends above all on the metabolic state of the individual. 
During hypoxia, GPBB is released from the bond a so-
called soluble form of GPBB predominates and escapes 
the cell through diﬀ  usion. The early release of GPBB into 
the blood is a common result of the combination of es-
calated glycogenolysis and increased permeability of cell 
Table 1. Distribution of GPBB ELISA in individuals by ACS presence
Individuals with non-STEMI (n = 20) Individuals without ACS (n = 20)
F ratio P
Parameter X Median SD Normality X Median SD Normality
GPBB 32.3 32.6 14.7 Yes 6.1 6.2 1.4 Yes 63.6 < 0.01
Fig. 1.  Interactive plot diagram for GPBB ELISA (μg/l) 
and non-STEMI presence (6 hours after the ad-
mission, AMI). AUC 1.0 (95 % CI 0.91 – 1.0).249 Use of Glycogen Phosphorylase BB measurement with POCT in the diagnosis of acute coronary syndromes. 
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membranes which is typical for myocardial ischemia and 
necrosis1.
Under physiological conditions, Glycogen Phospho-
rylase is a dimer (monomer has Mr 97 kDa), which is 
composed of two identical subunits (homodimer). Three 
enzymes are commonly found in human tissue – GPLL 
(liver isoform), GPMM (muscle isoform), and GPBB 
(brain isoform.) These isoenzymes are encoded by diﬀ  er-
ent genes and diﬀ  er in both structure and function. The 
BB isoenzyme is found in brain and heart muscle and in 
small amounts in striated muscles in other tissue as well 
(in leukocytes, spleen, kidneys, bladder, testes, liver, diges-
tive tract, and aorta)1. 
Following the results of clinical studies, GPBB can 
be regarded as a highly sensitive marker that is released 
1 to 4 hours after the onset of acute myocardial infarction 
(AMI), while 100 % of patients showed elevated GPBB 
after 4 to 5 hours1–3, 5. GPBB is also a sensitive marker for 
the detection of perioperational myocardial ischemia and 
it is possible that it could also be used as a marker of early 
reperfusion. Values normalize 1 to 2 days following the 
onset of AMI1, 4, 5, 8. False positives for increased GPBB 
are found in patients with trauma or signiﬁ  cant damage 
to the central nervous system7. 
It is highly interesting that GPBB also increases in 
patients with acute coronary syndrome without of myo-
cardial ischemia; the determination of GPBB has a high 
prognostic value for these individuals2, 3. It is likely that 
GPBB could, unlike myoglobin or troponins, identify myo-
cardial ischemia, since only GPBB increases above the 
upper reference limit during of these conditions3, 5. 
Commercial kits for determining GPBB levels were not 
available a few years ago (only in-house ELISA methods 
existed)2, 6, 10. Diagnostic kits have only recently appeared 
on the market (approved by the FDA and labelled CE) 
based on ELISA and for the POCT regime. Principle of 
the both tests is similar7. GPBB-ELISA (Enzyme-Linked 
Immunoadsorbent Assay) is a blood test for the early de-
tection of myocardial infarction. It works on an (sandwich 
assay, two antibodies) enzyme basis7. GPBB-POCT (The 
Point Of Care Test) is the successor of the ELISA test 
and an important supplement for the emergency ambu-
lances. It is a quick and qualitative test for making the 
ﬁ  rst decisions. POCT is a stripe test (lateral ﬂ  ow), which 
also functions on the GPBB basis. Its various layers are 
plated with small traces of monoclonal catch-antibody of 
GPBB. Another antibody, responsible for the colouring, 
is applied on the other side. Once the blood sample runs 
on the absorbent strap on the antibody track, GPBB is 
caught by the antibodies and made visible with the help 
of the antibody colouring. 50 μl are enough to gain a solid 
result. The time for testing only takes about 15 minutes7. 
GPBB-POCT test can be performed using full blood (test 
tube with lithium-heparin), plasma (lithium-heparin), or 
serum. In the event that GPBB is present in the sample 
in a concentration exceeding 10 μg/l a coloured line will 
appear (samples are evaluated as positive). An additional 
coloured line always appears to control the accuracy of 
the test. The manufacturer holds a patent on the produc-
tion and clinical use of this test7. 
Our results conﬁ  rmed the absolute correspondence be-
tween the results of the ELISA test and qualitative GPBB 
test in the POCT regime. We are aware of the qualifying 
fact that our test involved individuals with acute myocar-
dial infarction (non-STEMI) 6 hours following onset and 
their comparison with individuals without ACS, when 
with respect to time factors the determination of heart 
troponins is optimal for the diagnosis. Nevertheless, our 
goal in this work was not to conﬁ  rm the exceptionality of 
GPBB as a fast marker (this was previously conducted)11, 
but to conﬁ  rm the correspondence of GPBB results meas-
ured by ELISA and POCT.
 It is possible to conclude that GPBB from POCT 
provides, at the recommended cut-oﬀ   value results that 
are comparable with values determined by the ELISA test. 
It is reasonable to assume that the GPBB POCT test can 
expand the laboratory diagnostic palette in the ﬁ  rst hours 
following acute coronary syndrome. The veriﬁ  cation of 
the singular early diagnostic eﬃ   ciency of this test could 
even be interesting for manufacturers of automatic im-
muno-analytical systems.
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